High-permeability and low-sensitivity ripropylene dicaine wound dressing and preparation method thereof

By employing nano-penetration enhancement technology and moist heat sterilization, the problems of slow penetration and instability of liposome preparations have been solved, resulting in a wound dressing that is fast-acting, hypoallergenic, and highly stable, suitable for wound care.

CN120884566APending Publication Date: 2025-11-04HANGZHOU HEYAN MEDICAL BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202510859025.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-25
Publication Date
2025-11-04

AI Technical Summary

Technical Problem

Existing liprocaine formulations have poor penetration, slow onset of anesthesia, and are susceptible to oxidative degradation or hydrolysis, making them difficult to withstand moist heat sterilization, which affects efficacy and product quality.

Method used

Using nano-penetration enhancement technology, the average particle size of lidocaine and prilocaine is controlled to be 100-300nm. Combined with sodium hyaluronate, solvent, emulsifier, moisturizer, soothing agent and other ingredients, a highly permeable and hypoallergenic wound dressing is prepared and then sterilized by moist heat treatment.

Benefits of technology

It enables lidocaine and prilocaine to penetrate the skin quickly, have a rapid onset of action, good hypoallergenicity, can withstand moist heat sterilization, and has high stability, thus improving the efficacy and product quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120884566A_ABST
    Figure CN120884566A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medical and mechanical combinations, and discloses a high-permeability and low-sensitivity ripdicaine wound patch and a preparation method thereof.The high-permeability and low-sensitivity ripdicaine wound patch comprises a wound patch body, and the wound patch body is prepared from, by mass, 0.1%-0.4% of sodium hyaluronate, 1.5%-3.5% of lidocaine, 1.5%-3.5% of prilocaine, 3%-10% of solvent, 0.5%-8% of emulsifier, 2%-10% of humectant, 0.1%-5% of soothing agent, 0.1%-1.5% of stabilizer, 0.1%-1% of thickener and the balance water. According to the present invention, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, and the total amount of the raw materials is 100%. And the anesthetic has the advantages of quick effect taking, low sensitivity, capability of resisting moist heat sterilization and good stability.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The application relates to the technical field of pharmaceutical devices, in particular to a high-permeability and low-sensitivity lipocaine wound dressing and a preparation method thereof. BACKGROUND

[0002] Lidocaine-containing cream can be used for local dermal anesthesia. In recent years, many manufacturers have made lidocaine into ointment. Lidocaine ointment is very convenient. The ointment has a permeation effect on local mucosa and skin, and acts on superficial nerve endings to produce analgesic effect. The lidocaine ointment can also be applied to the object to be introduced, and after the ointment acts on the local contacted mucosa and skin, the person is more tolerant to the invasive operation and can more comfortably accept the medical supplies. However, the common adverse reactions are transient local reactions at the administration site, such as pallor, redness and edema. The initial burning sensation, itching or warmth at the administration site is usually mild. In particular, for patients with sensitive skin, greater allergic reactions can be caused.

[0003] According to the search of the Chinese invention patent (publication number CN118743691A), a lidocaine and prilocaine-containing wound repair dressing and a preparation process thereof are disclosed. The mass percentage components are as follows: 0.15-0.2% of sodium hyaluronate, 80.5-90.5% of purified water, 6-12% of polyethylene 40 hydrogenated castor oil, 0.05-0.15% of carbomer, 1.5-3.5% of lidocaine, 1.5-3.5% of prilocaine and 0.1-0.2% of preservative. The beneficial effects are as follows: the excellent analgesic effect, moisturizing ability and multifunctional characteristics not only significantly improve the effect of wound care, but also provide a more comfortable treatment experience for patients, and have a broad market application prospect.

[0004] The Chinese invention patent (publication number CN113398101B) discloses a compound lidocaine gel patch. The gel patch is made of the following components by weight percentage: 4-8% of lidocaine hydrochloride, 4-8% of prilocaine hydrochloride, 2-5% of a skeleton material, 5-10% of a filler, 20-30% of an adhesive, 3-9% of a tackifier, 1-5% of a crosslinking agent, 2-4% of a transdermal absorption enhancer, 30-50% of a humectant, 0.005-0.02% of a preservative, 0.005-0.02% of a complexing agent and 0.5-2% of a stabilizer. The compound lidocaine / prilocaine gel patch has stable quality, good treatment effect and simple preparation process, and can realize industrialized production.

[0005] A Chinese invention patent (publication number CN113797344A) discloses a compound lidocaine mask liquid for anesthesia, as well as a preparation method and application thereof. The mask liquid is prepared from the following components by weight: lidocaine 0.1-5 parts, prilocaine 0.1-5 parts, natural moisturizing agent 0.01-2 parts, chitosan substance 0.01-3 parts, cellulose substance 0.01-3 parts, azone substance 0.5-5 parts, diethylene glycol ethyl ether 1-10 parts, anti-allergic agent 0.02-3 parts, preservative 0.01-2 parts, basic substance 0.01-2 parts, and sterile water for injection 55-95 parts. The mask liquid has the characteristics of fast onset, high safety, convenient use, mildness, and no irritation. In addition, the preparation method of the compound lidocaine mask liquid is simple, the cost is low, and good economic benefits are achieved. The compound lidocaine mask liquid can also be used to make a mask. When used, the mask is directly taken out and applied to a specific position, and the operation is simple.

[0006] However, through actual application, it is found that the technical solution still has at least the following defects: The existing prilocaine preparation has poor penetration effect, slow onset of anesthesia, or incomplete anesthesia effect. The existing prilocaine preparation has instability problems such as oxidation degradation or hydrolysis during long-term storage and placement, and is prone to mask liquid layering. The prilocaine dosage form of the prior art is also difficult to withstand moist heat sterilization and radiation sterilization, and has problems in sterile protection. For use on wound sites, it affects the overall use effect and product quality.

[0007] Therefore, it is urgent to develop a prilocaine wound dressing that can quickly take effect, has stable quality, and can withstand moist heat sterilization. SUMMARY

[0008] The present application aims to provide a prilocaine wound dressing with high penetration and low sensitivity, and a preparation method thereof, to solve the problems raised in the background art. Based on the nano penetration promotion technology, the average particle size is controlled within the range of 100-300 nm, which can effectively promote the penetration of lidocaine and prilocaine into the epidermis and dermis of the skin, achieve rapid onset and anesthesia effect, and has the advantages of rapid onset, low sensitivity, resistance to moist heat sterilization, and good stability.

[0009] To achieve the above-mentioned purposes, the present application provides the following technical solutions: A high-permeability and low-sensitivity propidocaine wound dressing, preferably comprising a wound dressing, the wound dressing comprising, by mass percentage, 0.1-0.4% of sodium hyaluronate, 1.5-3.5% of lidocaine, 1.5-3.5% of prilocaine, 3-10% of a solvent, 0.5-8% of an emulsifier, 2-10% of a humectant, 0.1-5% of a soothing agent, 0.1-1.5% of a stabilizer, 0.1-1% of a thickening agent, and purified water added to 100%, the wound dressing containing propidocaine nanoemulsion, the propidocaine nanoemulsion having an average particle size in the range of 100-300 nm.

[0010] Preferably, as preferred, the wound dressing comprises, by mass percentage, 0.15-0.2% of sodium hyaluronate, 2-3% of lidocaine, 2-3% of prilocaine, 5-8% of a solvent, 1-5% of an emulsifier, 5-8% of a humectant, 0.5-3% of a soothing agent, 0.2-1% of a stabilizer, and 0.3-0.6% of a thickening agent, and purified water added to 100%.

[0011] Preferably, the solvent is one or both of medium-chain triglycerides and olive oil.

[0012] Preferably, the emulsifier is one or more of phospholipids, sodium lauryl sulfate, Tween 60 or 80, vitamin E polyethylene glycol succinate (TPGS), sorbitan monooleate, polyoxyethylene sorbitan monooleate, poloxamer, polyoxyethylene hydrogenated castor oil, and polyethylene glycol (15)-hydroxystearate.

[0013] Preferably, the phospholipids are one of soybean phospholipids and egg yolk lecithin.

[0014] Preferably, the humectant is one or more of glycerol, propylene glycol, 1,2-hexanediol, 1,2-pentanediol, polyethylene glycol 300, and polyethylene glycol 400.

[0015] Preferably, the soothing agent is one or more of trans-4-tert-butylcyclohexanol, bisabolol, olea europaea leaf extract, aescin, betaine, and dipotassium glycyrrhizinate.

[0016] Preferably, the stabilizer comprises a pH adjuster, an antioxidant, etc., and can be selected as one or more of alpha-tocopherol, disodium edetate, citric acid, triethanolamine, sodium hydroxide, ascorbic acid, or ascorbyl palmitate.

[0017] Preferably, the thickening agent is one or more of carbomer, xanthan gum, hydroxypropyl methylcellulose, and sodium carboxymethylcellulose, and the bacteriostatic agent is one or more of methylparaben, ethylparaben, sorbic acid, and benzyl alcohol.

[0018] The application discloses a preparation method of a high-permeability and low-sensitivity propivacaine wound dressing. S1: preparation of propivacaine nanoemulsion S1.1: weigh propivacaine, lidocaine, a solvent and an emulsifier into an emulsion preparation pot, set the jacket temperature of the emulsion preparation pot to 60-75 DEG C, the temperature in the pot to 50-70 DEG C, start heating until complete melting, and start stirring to obtain an oil phase; S1.2: add phospholipid and an emulsifier into a certain amount of purified water, shear until uniform, and preheat to 60-70 DEG C to obtain an aqueous phase; S1.3: add the aqueous phase into the oil phase, shear and emulsify at 60-70 DEG C and a rotating speed of 8000-20000 rpm for 10-30 min to obtain propivacaine primary emulsion; S1.4: homogenize the propivacaine primary emulsion by using a high-pressure homogenizer or a micro-jet homogenizer to obtain stable propivacaine nanoemulsion, adjust the pH to 7-8.5, and the average particle size of the nanoemulsion is 100-300 nm.

[0019] S2: preparation of a mask liquid S2.1: add sodium hyaluronate and a thickening agent into purified water, stir and disperse until uniform, and swell completely to be transparent, and record as an aqueous phase 1; S2.2: add a soothing agent, a moisturizing agent and a bacteriostatic agent into purified water, stir and dissolve uniformly, and record as an aqueous phase 2; S2.3: add the aqueous phase 2 into the aqueous phase 1, start stirring, the stirring rotating speed is 500-2000 rpm, and the total stirring time is kept for 10-30 min to obtain a mixed liquid; S2.4: add the propivacaine nanoemulsion into the mixed liquid, start stirring, the stirring rotating speed is 500-2000 rpm, and the total stirring time is kept for 30-60 min to obtain the mask liquid, the pH of the mask liquid is 7-8.5, the viscosity is 500-2000 mPa s, the average particle size is 100-300 nm, and the PDI is less than 0.2.

[0020] S3: preparation of a dressing S3.1: put non-woven fabric with a specific shape into an aluminum foil bag, the specific shape includes an oval shape, a human face shape and a right-angle square shape; S3.2: fill the mask liquid into the aluminum foil bag and seal the bag.

[0021] S3.3: sterilize the sealed dressing at 121 DEG C for 8-12 min under wet heat.

[0022] S3.4: after cooling, perform outer packaging to obtain the propivacaine wound dressing.

[0023] The technical scheme has the beneficial effects that: The present application is based on nano penetration technology, the average particle size is controlled in the range of 100-300nm, can effectively promote lidocaine and prilocaine to penetrate into the epidermis and dermis of the skin, can quickly take effect to achieve anesthetic effect, has the advantages of rapid effect, low sensitivity, can resist moist heat sterilization, good stability. BRIEF DESCRIPTION OF DRAWINGS

[0024] Figure 1 The preparation flowchart provided by the present application is provided. DETAILED DESCRIPTION

[0025] The present application is not limited to the following examples, and it should be noted that in each example, the amount of each component in the prescription is "calculated by weight" unless otherwise specified.

[0026] Example 1: The present application provides a lidocaine and prilocaine wound dressing, and the preparation method comprises the following steps: S1: Preparation of lidocaine and prilocaine nanoemulsion S1.1: Weigh the prilocaine, lidocaine, medium-chain triglyceride, alpha-tocopherol and polyethylene glycol (15)-hydroxystearate into the emulsion preparation pot, set the emulsion preparation pot jacket temperature to 70℃, the pot temperature to 70℃, start heating, until completely melted, and start stirring, get the oil phase; S1.2: Add egg yolk lecithin to a certain amount of purified water, shear until uniform, and preheat to 70℃, get the water phase; S1.3: Add the above obtained water phase to the above obtained oil phase, shear emulsify at 70℃ for 30min at a speed of 12000rpm, get the lidocaine and prilocaine primary emulsion; S1.4: The obtained lidocaine and prilocaine primary emulsion is subjected to homogenization treatment by high-pressure homogenizer or micro-jet homogenizer, the homogenization pressure is 1200bar, and stable lidocaine and prilocaine nanoemulsion is obtained, the pH is adjusted to 8.5 with citric acid solution, and the particle size of the obtained nanoemulsion is 182nm.

[0027] S2: Preparation of mask liquid S2.1: Add sodium hyaluronate, sodium carboxymethyl cellulose and carbomer to purified water, stir and disperse uniformly, swell completely, and become transparent, record as water phase 1; S2.2: Add 4-tert-butylcyclohexanol, glycerol, propylene glycol and nipagin methyl ester to purified water, stir and dissolve uniformly, record as water phase 2, and nipagin methyl ester needs to be dissolved in 80℃ hot water.

[0028] S2.3: The above water phase 2 was added to the above water phase 1, and stirring was started at a stirring speed of 1000 rpm, and the total stirring time was kept at 20 min to obtain a mixture; S2.4: The propylbuprocaine nanoemulsion was added to the above obtained mixture, and stirring was started at a stirring speed of 1000 rpm, and the total stirring time was kept at 30 min to obtain a mask liquid, the pH of the mask liquid was 8.5, the viscosity was 1620 mPa·s, the average particle size was 191 nm, and the PDI was 0.187.

[0029] S3: Preparation of the patch S3.1: A non-woven fabric with a specific shape was put into an aluminum foil bag; S3.2: The mask liquid was filled into the aluminum foil bag and sealed.

[0030] S3.3: The above sealed patch was subjected to moist heat sterilization at 121 ℃ for 12 min.

[0031] S3.4: After cooling, the patch was packaged to obtain a propylbuprocaine wound patch.

[0032] Example 2: The present embodiment provides a propylbuprocaine wound patch, and the preparation method thereof comprises the following steps: S1: Preparation of propylbuprocaine nanoemulsion S1.1: The weighed propylbuprocaine, lidocaine, medium-chain triglyceride, ascorbyl palmitate, polyoxyethylene hydrogenated castor oil, and polyethylene glycol (15)-hydroxystearate were put into an emulsion preparation pot, the jacket temperature of the emulsion preparation pot was set to 70 ℃, the pot temperature was set to 70 ℃, the temperature was started to rise, and the mixture was completely melted, and stirring was started to obtain an oil phase; S1.2: The egg yolk lecithin was added to a certain amount of purified water, sheared to be uniform, and preheated to 70 ℃ to obtain a water phase; S1.3: The above obtained water phase was added to the above obtained oil phase, sheared and emulsified at 70 ℃ and a speed of 12000 rpm for 15 min to obtain a propylbuprocaine primary emulsion; S1.4: The obtained propylbuprocaine primary emulsion was subjected to homogenization treatment by a high-pressure homogenizer or a micro-jet homogenizer, the homogenization pressure was 1000 bar, and a stable propylbuprocaine nanoemulsion was obtained, the pH of which was adjusted to 8.5 by citric acid solution, and the average particle size of the above obtained nanoemulsion was 228 nm.

[0033] S2: Preparation of a mask liquid S2.1: The sodium hyaluronate, sodium carboxymethyl cellulose, and carbomer were added to purified water, stirred and dispersed uniformly, swelled completely, and became transparent, and the mixture was recorded as water phase 1; S2.2: Put sodium aescinate, dipotassium glycyrrhizinate, glycerol, propylene glycol and nipagin methyl ester into purified water, stir until dissolved, and record as water phase 2. Nipagin methyl ester needs to be dissolved in 80℃ hot water.

[0034] S2.3: Put water phase 2 into water phase 1, start stirring, stirring speed is 1000 rpm, total stirring time is 20 min, and a mixed solution is obtained. S2.4: Put propylbucain nanometer emulsion into the mixed solution, start stirring, stirring speed is 1000 rpm, total stirring time is 30 min, and a mask solution is obtained. The pH of the mask solution is 8.5, the viscosity is 1707 mPa·s, the average particle size is 235 nm, and the PDI is 0.153.

[0035] S3: Preparation of the patch S3.1: Put non-woven fabric with a specific shape into an aluminum foil bag. S3.2: Fill the mask solution into the aluminum foil bag and seal.

[0036] S3.3: Sterilize the sealed patch at 121℃ for 12 min.

[0037] S3.4: After cooling, the patch is packaged, and a propylbucain wound patch is obtained.

[0038] Example 3: The embodiment provides a propylbucain wound patch, and a preparation method thereof includes the following steps: S1: Preparation of propylbucain nanometer emulsion S1.1: Put weighed procaine, lidocaine, medium-chain triglyceride, ascorbyl palmitate and vitamin E polyethylene glycol succinate (TPGS) into an emulsion preparation pot, set the pot jacket temperature to 70℃, the pot temperature to 70℃, start heating until completely melted, and start stirring to obtain an oil phase. S1.2: Put egg yolk lecithin into a certain amount of purified water, shear until uniform, and preheat to 70℃ to obtain an aqueous phase. S1.3: Put the obtained aqueous phase into the obtained oil phase, shear emulsify at 70℃ and 15000 rpm for 15 min to obtain a propylbucain primary emulsion. S1.4: The obtained propylbucain primary emulsion is subjected to homogenization treatment by a high-pressure homogenizer or a micro-jet homogenizer, the homogenization pressure is 1200 bar, a stable propylbucain nanometer emulsion is obtained, the pH is adjusted to 8.5 by citric acid solution, and the average particle size of the obtained nanometer emulsion is 234 nm.

[0039] S2: Preparation of a mask solution S2.1: Sodium hyaluronate, sodium carboxymethyl cellulose and carbomer were added into purified water, stirred and dispersed uniformly, swelled completely and became transparent, recorded as water phase 1; S2.2: Dipotassium glycyrrhizinate, glycerol, polyethylene glycol 300 and nipagin methyl ester were added into purified water, stirred and dissolved uniformly, recorded as water phase 2, and nipagin methyl ester was dissolved in hot water at 80°C.

[0040] S2.3: The water phase 2 was added into the water phase 1, and stirring was started with a stirring speed of 1000 rpm, and the total stirring time was kept for 20 min to obtain a mixed solution; S2.4: The propylbuprocaine nanoemulsion was added into the mixed solution, and stirring was started with a stirring speed of 1000 rpm, and the total stirring time was kept for 30 min to obtain a mask solution, the pH of the mask solution was 8.5, the viscosity was 1620 mPa·s, the average particle size was 255 nm, and the PDI was 0.189.

[0041] S3: Preparation of the patch S3.1: A non-woven fabric with a specific shape was put into an aluminum foil bag; S3.2: The mask solution was filled into the aluminum foil bag and sealed.

[0042] S3.3: The sealed patch was subjected to moist heat sterilization at 121°C for 8 min.

[0043] S3.4: After cooling, the patch was packaged, and a propylbuprocaine wound patch was obtained.

[0044] Comparative Example 1: The embodiment provides a propylbuprocaine wound patch, and a preparation method thereof includes the following steps: S1: Preparation of a mask solution: S1.1: The weighed prilocaine, lidocaine and polyoxyethylene hydrogenated castor oil were put into an emulsion preparation pot, the pot jacket temperature and the pot temperature were set to 70°C, the temperature was started to rise until complete melting, and stirring was started to obtain an oil phase; S1.2: Sodium hyaluronate, sodium carboxymethyl cellulose and carbomer were added into purified water, stirred and dispersed uniformly, swelled completely and became transparent, recorded as water phase 1; S1.3: Glycerol and propylene glycol were added into purified water, stirred and dissolved uniformly, recorded as water phase 2; S1.4: The water phase 2 was added into the water phase 1, and stirring was started with a stirring speed of 1000 rpm, and the total stirring time was kept for 20 min to obtain a mixed solution, and the temperature was preheated to 70°C; S1.5: The above oil phase was added to the above obtained mixture, and shearing was started with a shearing speed of 10000 rpm, and the total stirring time was kept at 30 min, to obtain a mask liquid, the pH of the mask liquid was 8.5, the viscosity was 1464 mPa-s, the average particle size was greater than 300 nm, and the PDI was 0.893, indicating that the particle size distribution was wide.

[0045] S2: Preparation of the patch: (1) A non-woven fabric with a specific shape was put into an aluminum foil bag; (2) The mask liquid was filled into the aluminum foil bag and sealed.

[0046] (3) The above sealed patch was subjected to moist heat sterilization at 121℃ for 8 min.

[0047] (4) After cooling, the outer package was obtained, and the lidocaine wound patch was obtained.

[0048] The comparison results before and after sterilization of Examples 1-3 and the comparative examples are as follows: As shown in the above table, the lidocaine wound patch of the present application can withstand moist heat sterilization, and the properties and particle size do not change obviously before and after sterilization, while the comparative examples using the prior art cannot withstand moist heat sterilization, and are emulsion broken and layered after sterilization.

[0049] Example 4: Effect evaluation 1. Allergic test: Ten white mice were selected, the back of each experimental mouse was shaved, and the back of the mouse was divided into two areas, each area was about 6 cm2, and the patches prepared by Example 1 and Comparative Example 1 were respectively attached to the two different areas of the back of the mouse, and the back condition of the 10 mice was observed after 3 hours of patching.

[0050] After 3 hours, among them, 3 mice did not have allergic reactions such as redness, rash, and bubbles in the two areas of the back, and did not have conditions such as rapid breathing, indicating that the 3 mice had no allergic reactions to the anesthetic patch. However, the remaining 7 mice had different degrees of reaction in the two different areas of the back, but the area of the patch of Example 1 did not have allergic reactions such as redness and blistering, while the area of Comparative Example 1 had obvious allergic reactions such as redness and blistering, and the addition of the soothing agent could have a certain soothing effect.

[0051] 2. Irritation test: Six mice are selected for stimulation experiment. Firstly, the back surface of three mice is cleaned, then the six mice are numbered as 1, 2, 3, 4, 5, 6 respectively, and the patches of Example 1 (1, 2, 3) and Comparative Example 1 (unsterilized) (4, 5, 6) are attached respectively, and the attached area is 20 cm2. Then, the back skin of the mice is pricked with a sterilized needle, and the bleeding is 1 degree, then the back state is observed at 1 h, 5 h, 10 h, 15 h respectively, and the back state of each mouse is as follows: The above is only an embodiment of the present application, and the specific technical solutions and / or common knowledge of the scheme are not described in detail. It should be noted that for those skilled in the art, without departing from the technical solutions of the present application, a number of modifications and improvements can be made, which should also be considered as the protection scope of the present application, and these will not affect the effect and practicality of the patent. The protection scope of the present application should be subject to the content of its claims, and the specific implementation mode and the like recorded in the specification can be used to explain the content of the claims.

Claims

1. A highly permeable and hypoallergenic lipoic acid wound dressing, characterized in that: The invention includes a wound dressing, which, by weight percentage, comprises 0.1-0.4% sodium hyaluronate, 1.5-3.5% lidocaine, 1.5-3.5% prilocaine, 3-10% solvent, 0.5-8% emulsifier, 2-10% moisturizer, 0.1-5% soothing agent, 0.1-1.5% stabilizer, 0.1-1% thickener, and purified water to 100%. The wound dressing contains prilocaine nanoemulsion, wherein the average particle size of the prilocaine nanoemulsion ranges from 100-300 nm.

2. The highly permeable and hypoallergenic lipofuscin wound dressing according to claim 1, characterized in that: Preferably, the wound dressing comprises, by weight percentage, 0.15-0.2% sodium hyaluronate, 2-3% lidocaine, 2-3% prilocaine, 5-8% solvent, 1-5% emulsifier, 5-8% moisturizer, 0.5-3% soothing agent, 0.2-1% stabilizer, 0.3-0.6% thickener, and purified water to 100%.

3. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The solvent is one or both of medium-chain triglycerides and olive oil.

4. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The emulsifier is one or more of the following: phospholipids and sodium lauryl sulfate, Tween 60 or 80, vitamin E polyethylene glycol succinate (TPGS), sorbitan monooleate, polyoxyethylene dehydrated sorbitan monooleate, poloxamer, polyoxyethylene hydrogenated castor oil, and polyethylene glycol (15)-hydroxystearate.

5. The highly permeable and hypoallergenic lipofuscin wound dressing according to claim 4, characterized in that: The phospholipid is one of soybean phospholipids or egg yolk lecithin.

6. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The moisturizer is one or more of glycerin, propylene glycol, 1,2-hexanediol, 1,2-pentanediol, polyethylene glycol 300, and polyethylene glycol 400.

7. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The soothing agent is one or more of the following: trans-4-tert-butylcyclohexanol, bisabolol, olive leaf extract, aescin, betaine, and dipotassium glycyrrhizate.

8. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The stabilizer includes pH adjusters, antioxidants, etc., and may be selected from one or more of α-tocopherol, disodium edetate, citric acid, triethanolamine, sodium hydroxide, ascorbic acid, or ascorbyl palmitate.

9. A highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that: The thickener is one or more of carbomer, xanthan gum, hydroxypropyl methylcellulose, and sodium carboxymethyl cellulose, and the antibacterial agent is one or more of methylparaben, ethylparaben, sorbic acid, and benzyl alcohol.

10. A method for preparing a highly permeable and hypoallergenic lipofuscin wound dressing according to any one of claims 1-2, characterized in that, The following technical solution is adopted: S1: Preparation of Liprocaine Nanoemulsion S1.1: Weigh out prilocaine, lidocaine, solvent and emulsifier into the emulsion preparation pot, set the jacket temperature of the emulsion preparation pot to 60-75°C and the pot temperature to 50-70°C, start heating until completely melted, and start stirring to obtain the oil phase; S1.2: Add phospholipids and emulsifiers to a certain amount of purified water, shear until homogeneous, and preheat to 60-70℃ to obtain the aqueous phase; S1.3: Add the above aqueous phase to the above oil phase, and shear emulsify at 60-70°C and 8000-20000 rpm for 10-30 min to obtain propylcaine primary emulsion; S1.4: The above-mentioned levodicaine colostrum is homogenized by a high-pressure homogenizer or a microfluidic homogenizer to obtain a stable levodicaine nanoemulsion. The pH is adjusted to 7-8.5, and the average particle size of the nanoemulsion is in the range of 100-300 nm. S2: Preparation of Facial Mask Liquid S2.1: Add sodium hyaluronate and thickener to purified water and stir to disperse evenly. Once fully swollen and transparent, this phase is designated as aqueous phase 1. S2.2: Add the soothing agent, moisturizer, and antibacterial agent to purified water, stir until dissolved, and record this as aqueous phase 2; S2.3: Add the above aqueous phase 2 to the above aqueous phase 1, turn on the stirrer, the stirring speed is 500-2000 rpm, and the total stirring time is maintained at 10-30 min to obtain a mixture; S2.4: Add the above-mentioned propylcaine nanoemulsion to the above mixture, start stirring, stir at a speed of 500-2000 rpm, and maintain the total stirring time at 30-60 min to obtain a mask liquid. The mask liquid has a pH of 7-8.5, a viscosity of 500-2000 mPa·s, an average particle size of 100-300 nm, and a PDI of less than 0.

2. S3: Preparation of the dressing S3.1: Pack non-woven fabric of a specific shape into an aluminum foil bag. The specific shape includes oval, face shape and right-angled square. S3.2: Fill the above-mentioned facial mask liquid into an aluminum foil bag and seal it. S3.3: Apply the sealed dressing at 121℃ for 8-12 minutes for moist heat sterilization. S3.4: After cooling, the outer packaging is used as the Delipro dicaine wound dressing.

Citation Information

Patent Citations

  • A compound lidocaine gel patch

    CN113398101B

  • Compound lidocaine mask liquid for anesthesia as well as preparation method and application thereof

    CN113797344A

  • Wound repair application containing lidocaine and prilocaine and preparation process of wound repair application

    CN118743691A

Cited By

  • Levadicaine pre-packaging application and preparation method thereof

    CN121695112A

  • A pre-packaged lidocaine patch and method of making same

    CN121695112B